Adulterated Misbranded - Mpje
- Which term applies when a drug is an imitation of another drug (copy intended to deceive)?
- Misbranded. Imitating another drug misleads about identity, fitting FDCA misbranding provisions under section 502(i)(2).
- Which term applies when a drug is held under conditions that could render it injurious to health?
- Adulterated. Holding under conditions risking injury to health may cause contamination or degradation, adulterating the drug per FDCA.
- Identify the classification: a drug is stored outside labeled temperature range causing potency loss.
- Adulterated. Storage outside specified temperatures can degrade potency, adulterating the drug by altering its strength or quality below standards.
- Identify the classification: a prescription drug is dispensed without the required Rx-only legend.
- Misbranded. Dispensing without the 'Rx only' legend omits required prescription status information, constituting misbranding under FDCA.
- Identify the classification: a drug label omits required directions for use for laypersons.
- Misbranded. Omitting required directions for layperson use violates FDCA labeling requirements, constituting misbranding by lacking adequate usage information.
- Identify the classification: a container is missing required information such as manufacturer/packer/distributor.
- Misbranded. Missing required details like manufacturer information on containers violates FDCA labeling standards, leading to misbranding.
- Identify the classification: a lot is past its expiration date and is held for dispensing.
- Adulterated. Expired products may no longer meet quality or potency standards, thus are considered adulterated when held for dispensing.
- Identify the classification: a drug has been diluted or substituted so it is not the drug it purports to be.
- Adulterated. Dilution or substitution changes the drug's identity or strength from what is purported, constituting adulteration under FDCA.
- Identify the classification: a product's label claims an unapproved use in a way that is misleading.
- Misbranded. Misleading claims of unapproved uses provide false information on indications, violating FDCA misbranding rules.
- Identify the classification: a pharmacy repackages a drug but the new label lacks lot number or expiration.
- Misbranded. Repackaged drugs lacking lot number or expiration violate FDCA labeling requirements, deeming them misbranded.
- Identify the classification: labeling is false or misleading in any particular.
- Misbranded. False or misleading labeling in any aspect deceives consumers, directly meeting the FDCA criteria for misbranding.
- Identify the classification: a drug's container is made of poisonous or deleterious material.
- Adulterated. Containers with poisonous or deleterious materials can leach contaminants, adulterating the drug per FDCA section 501(a)(3).
- Identify the classification: tamper-evident packaging is required but missing on an OTC product.
- Misbranded. Omission of required tamper-evident packaging fails to meet FDCA safety labeling standards, resulting in misbranding.
- What is the legal meaning of a misbranded drug under the FDCA (core concept)?
- Misbranded: labeling or packaging is false, misleading, or legally inadequate. Under the FDCA, misbranding involves false, misleading, or inadequate labeling or packaging that fails to meet required standards.
- Identify the classification: the product was prepared, packed, or held under insanitary conditions.
- Adulterated. Insanitary conditions during preparation, packing, or holding risk contamination, deeming the drug adulterated per FDCA section 501(a)(2)(A).
- What term applies when a drug's labeling fails to bear the established (generic) name when required?
- Misbranded. Failure to include the established generic name violates FDCA labeling rules, resulting in misbranding for improper identification.
- What is the legal meaning of an adulterated drug under the FDCA (core concept)?
- Adulterated: product quality is compromised (e.g., contaminated, unsafe, substandard). The FDCA defines adulteration as compromise in a drug's quality, strength, purity, or safety due to factors like contamination or substandard conditions.
- Which term applies when a drug's identity, strength, quality, or purity falls below compendial standards?
- Adulterated. Falling below compendial standards for identity, strength, quality, or purity meets FDCA criteria for adulteration under section 501(b).
- What term applies when required warnings (e.g., habit-forming, pediatric risk) are missing from labeling?
- Misbranded. Absence of mandated warnings fails to inform users of risks, classifying the drug as misbranded under FDCA requirements.
- Identify the classification: a product is counterfeit (false labeling of identity or source).
- Misbranded. Counterfeit products feature false labeling of identity or source, classifying them as misbranded under FDCA provisions.
- Identify the classification: a drug is contaminated with microorganisms due to poor aseptic technique.
- Adulterated. Microbial contamination from poor aseptic technique impairs purity and safety, rendering the drug adulterated under FDCA.
- Identify the classification: a product contains filthy, putrid, or decomposed substance.
- Adulterated. Presence of filthy, putrid, or decomposed substances contaminates the product, rendering it adulterated under FDCA section 501(a)(1).
- What term applies when the quantity of contents statement on the package is absent or incorrect?
- Misbranded. Absent or incorrect quantity statements omit essential content details, misbranding the product per FDCA section 502(b)(2).
- What term applies when a drug's strength differs from what it purports or is represented to have?
- Adulterated. Deviation in strength from purported or represented levels compromises quality, classifying the drug as adulterated under FDCA.
- Identify the classification: a product is sourced from an unlicensed supplier and its pedigree is unverifiable.
- Adulterated. Unverifiable pedigree from unlicensed sources raises authenticity concerns, rendering the drug adulterated due to potential compromise.